chartexchange

Amarin: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 11, 2026 5:15 PM EST

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Amarin (NASDAQ:AMRN) announced its return to profitability following corporate restructuring and reduced operating expenses. The cardiovascular drug maker generated $9 million in operating cash flow through its existing international distribution partnerships across Europe. Three takeaways from management's comments highlight where the business is headed. Amarin reduced operating expenses nearly by half after streamlining its business. It generated $9 million in operating cash flow during the quarter, helping deliver $245,000 in net income despite price pressure from U.S. generic competitors. Continue reading

Read original article